Zagreb

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis3 trials
• Familial hypercholesterolaemia2 trials
• Coronary artery disease1 trial
• Heart failure1 trial
• Stroke1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 37 trials

Status

• Active, not recruiting4 trials
• Completed1 trial
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Novartis Pharmaceuticals7 trials

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

  NCT04926818· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis1 recruiting

Closed trials

• Terminated

  Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

  NCT04251533· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

  NCT03785405· Phase 3· Novartis Pharmaceuticals· Source